title: Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals.
abstract: Antigenic peptides derived from several differentiation antigens of the melanocyte lineage were recently identified in human melanomas as targets for HLA-A2.1-restricted cytotoxic T lymphocytes (CTLs). To examine their potential role in tumour-directed immune responses in vivo, we determined CTL reactivity against seven antigenic peptides derived from the Melan A/MART-1, tyrosinase and gp100/Pmel17 antigens in the peripheral blood of 10 HLA-A2+ healthy controls and 26 HLA-A2+ melanoma patients. The influenza matrix peptide (GILGFVFTL) presented by HLA-A2.1 was used as a control peptide. CTL reactivity was assessed in a mixed lymphocyte 'peptide' culture assay. Reactivity against Melan A/MART-1-derived peptide antigens was readily detectable in both melanoma patients and controls. Reactivity directed against tyrosinase-derived peptide antigens was also detected in both melanoma patients and healthy individuals, but less frequently. A measurable response against gp100/Pmel17-derived antigens was found in 1/10 controls and in 1/26 of the melanoma patients. Reactivity against the influenza matrix peptide was common in both melanoma patients and controls. Our findings show that precursor CTLs against melanocyte differentiation antigens can be detected in peripheral blood of melanoma patients and healthy individuals. The pattern of CTL reactivity directed against melanoma-associated antigens does not seem to be altered in melanoma patients. Despite antigen-specific CTL reactivity, tumour growth was not prevented in melanoma patients and autoimmune phenomena were not detected in healthy individuals. It remains to be determined whether precursor CTLs recognizing melanocyte differentiation antigens can be activated by immunization and lead to effective tumour rejection in vivo.
authors.affiliation: II Medizinische Klinik, Krankenhaus Nordwest, Frankfurt, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Jäger
authors.forename: M
authors.initials: M
authors.lastname: Ringhoffer
authors.forename: M
authors.initials: M
authors.lastname: Arand
authors.forename: J
authors.initials: J
authors.lastname: Karbach
authors.forename: D
authors.initials: D
authors.lastname: Jäger
authors.forename: C
authors.initials: C
authors.lastname: Ilsemann
authors.forename: M
authors.initials: M
authors.lastname: Hagedorn
authors.forename: F
authors.initials: F
authors.lastname: Oesch
authors.forename: A
authors.initials: A
authors.lastname: Knuth
mesh_terms: D000595:Amino Acid Sequence; D000943:Antigens, Differentiation / Q000097:blood*; D000951:Antigens, Neoplasm / Q000097:blood* / Q000494:pharmacology; D006801:Humans; D058965:MART-1 Antigen; D008545:Melanoma / Q000097:blood*; D008562:Membrane Glycoproteins; D014442:Monophenol Monooxygenase / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000494:pharmacology; D011506:Proteins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured; D058951:gp100 Melanoma Antigen
chemical_list: D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D058965:MART-1 Antigen; C548667:MLANA protein, human; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C548637:PMEL protein, human; D011506:Proteins; D058951:gp100 Melanoma Antigen; D014442:Monophenol Monooxygenase